Targacept, Inc. 200 East First Street, Suite 300 Winston-Salem, NC 27101-4165 Therapeutic Focus:  Central nervous system diseases and disorders Therapeutic Targets:  Neuronal nicotinic receptors (NNRs), which are key regulators of the nervous system Product Candidates:  AZD3480 (TC-1734) for conditions marked by cognitive impairment, including Alzheimer's disease and cognitive dysfunction in schizophrenia; TC-6499 for neuropathic pain; TC-5214 for Major Depressive Disorder; TC-2216 for depression/anxiety disorders; and TC-5619, for cognitive disorders/schizophrenia.

President & CEO:  J. Donald deBethizy, Ph.D. Number of Employees:  108 Date Established:  March 1997 IPO Completed:  April 2006 NASDAQ Ticker Symbol:  TRGT

Strategic Alliances:

  Exclusive global license and research collaboration with AstraZeneca AB for the development and commercialization of AZD3480 (TC-1734) to treat Alzheimer’s disease, cognitive dysfunction in schizophrenia and other cognitive disorders, as well as a multi-year research collaboration.

In addition, as of November 2007, AstraZeneca secured a future option for an exclusive license to TC-5619.

Exclusive global strategic alliance with GlaxoSmithKline focused in five therapeutic areas: pain, smoking cessation, obesity, addiction and Parkinson's disease.

Intellectual Property:  Pentad^TM, a proprietary drug discovery platform; and an extensive patent estate covering compounds that act on NNRs

Product: 

Inversine® (mecamylamine HCl), indicated for the treatment of moderately severe to severe essential hypertension and for uncomplicated cases of malignant hypertension